PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced its plan to host a 2024 Summer Series of R&D webinars that highlight multiple clinical stage RNA interference (RNAi) based medicines that utilize the company’s proprietary Targeted RNAi Molecule (TRiMTM) platform.

加利福尼亚州帕萨迪纳（商业新闻短讯）--箭头制药公司（NASDAQ:ARWR）今天宣布计划举办2024年夏季系列研发网络研讨会，重点介绍基于多临床阶段RNA干扰（RNAi）的药物，这些药物利用该公司专有的靶向RNAi分子（TRiMTM）平台。

Each webinar in the Summer Series will focus on a specific therapeutic area and will feature presentations by Arrowhead team members about the company’s clinical candidates and external key opinion leaders, who will discuss the respective disease areas and treatment landscapes..

夏季系列的每一场网络研讨会都将侧重于特定的治疗领域，并将由箭头团队成员介绍公司的临床候选人和外部关键意见领袖，他们将讨论各自的疾病领域和治疗领域。。

2024 Summer Series Schedule:

2024年夏季系列计划：

Muscular – ARO-DUX4 and ARO-DM1

肌肉–ARO-DUX4和ARO-DM1

Date: May 23, 2024

日期：2024年5月23日

Time: 2:00 pm ET

时间：美国东部时间下午2:00

Cardiometabolic – Plozasiran and zodasiran

心脏代谢-普洛扎西兰和唑达西兰

Date: June 25, 2024

日期：2024年6月25日

Time: TBD

时间：待定

Pulmonary – ARO-RAGE, ARO-MUC5AC, ARO-MMP7

肺–ARO-RAGE，ARO-MUC5AC，ARO-MMP7

Date: July 16, 2024

日期：2024年7月16日

Time: TBD

时间：待定

Obesity/Metabolic – ARO-INHBE and one additional new program to be disclosed

肥胖/代谢-ARO-INHBE和一个额外的新程序将被披露

Date: August 15, 2024

日期：2024年8月15日

Time: TBD

时间：待定

Central Nervous System – Platform and pipeline updates

中枢神经系统-平台和管道更新

Date: September 25, 2024

日期：2024年9月25日

Time: TBD

时间：待定

Christopher Anzalone, Ph.D., President and CEO at Arrowhead, said: “Arrowhead has made significant progress this year with our pipeline. We now have 14 investigational RNAi-based medicines in the clinic that leverage Arrowhead’s proprietary TRiMTM platform, four of which are in late-stage development.

Arrowhead总裁兼首席执行官Christopher Anzalone博士表示：“Arrowhead今年在我们的渠道方面取得了重大进展。我们现在在临床上有14种基于RNAi的研究性药物，利用Arrowhead专有的TRiMTM平台，其中四种处于后期开发阶段。

We are excited to launch the 2024 Summer Series of R&D webinars, which will provide an overview of the respective treatment landscapes, the biological rationale and preclinical data supporting each target, and our clinical development strategy for each pipeline program to be highlighted.”.

我们很高兴推出2024年夏季系列研发网络研讨会，该研讨会将概述各自的治疗情况，支持每个目标的生物学原理和临床前数据，以及我们针对每个管道计划的临床开发策略。”。

Each event will be approximately 90 minutes in duration with live webcasts and replays available on the Events and Presentations page under the Investors section of the Arrowhead website. Registration links and additional details regarding times, agendas, and speakers will be provided on the Arrowhead website and social media channels prior to each event..

每个活动将持续约90分钟，可在箭头网站投资者部分的活动和演示页面上进行实时网络广播和重播。在每次活动之前，箭头网站和社交媒体渠道将提供注册链接以及有关时间、议程和发言人的其他详细信息。。

About Arrowhead Pharmaceuticals

关于箭头制药

Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep, and durable knockdown of target genes.

箭头制药公司（Arrowhead Pharmaceuticals）通过沉默导致顽固性疾病的基因来开发治疗顽固性疾病的药物。使用广泛的RNA化学组合和有效的递送方式，箭头疗法触发RNA干扰机制，以诱导靶基因的快速，深入和持久的敲低。

RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing..

RNA干扰（RNAi）是活细胞中存在的一种机制，可抑制特定基因的表达，从而影响特定蛋白质的产生。Arrowhead基于RNAi的疗法利用了这种基因沉默的自然途径。。

For more information, please visit www.arrowheadpharma.com, or follow us on X (formerly Twitter) at @ArrowheadPharma or on LinkedIn. To be added to the Company's email list and receive news directly, please visit http://ir.arrowheadpharma.com/email-alerts.

欲了解更多信息，请访问www.arrowheadharma.com，或通过X（以前的推特）关注我们@arrowheadharma或LinkedIn。要添加到公司的电子邮件列表并直接接收新闻，请访问http://ir.arrowheadpharma.com/email-alerts.

Safe Harbor Statement under the Private Securities Litigation Reform Act:

私人证券诉讼改革法案下的安全港声明：

This news release contains forward-looking statements within the meaning of the 'safe harbor' provisions of the Private Securities Litigation Reform Act of 1995. Any statements contained in this release except for historical information may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as “may,” “will,” “expect,” “believe,” “anticipate,” “hope,” “intend,” “plan,” “project,” “could,” “estimate,” “continue,” “target,” “forecast” or “continue” or the negative of these words or other variations thereof or comparable terminology are intended to identify such forward-looking statements.

本新闻稿包含1995年《私人证券诉讼改革法案》中“安全港”条款所指的前瞻性声明。除历史信息外，本版本中包含的任何声明都可能被视为前瞻性声明。在不限制上述一般性的情况下，诸如“可能”、“将”、“预期”、“相信”、“预期”、“希望”、“打算”、“计划”、“项目”、“可能”、“估计”、“继续”、“目标”、“预测”或“继续”等词语或其其他变体或类似术语的否定词旨在识别此类前瞻性陈述。

In addition, any statements that refer to projections of our future financial performance, trends in our business, expectations for our product pipeline or product candidates, including anticipated regulatory submissions and clinical program results, prospects or benefits of our collaborations with other companies, or other characterizations of future events or circumstances are forward-looking statements.

此外，任何涉及我们未来财务业绩预测、业务趋势、对我们产品线或候选产品的期望的陈述，包括预期的监管提交和临床计划结果、我们与其他公司合作的前景或利益，或未来事件或情况的其他特征，都是前瞻性陈述。

These forward-looking statements include, but are not limited to, statements about the initiation, timing, progress and results of our preclinical studies and clinical trials, and our research and development programs; our expectations regarding the potential benefits of the partnership, licensing and/or collaboration arrangements and other strategic arrangements and transactions we have entered into or may enter into in the future; our beliefs and expectations regarding milestone, royalty or other payments that could be due to or from third parties under existing agreements; and our estimates regarding future revenues, research and development expenses, capital requirements and payments to third parties.

这些前瞻性陈述包括但不限于关于我们的临床前研究和临床试验以及我们的研究和开发计划的开始，时间，进展和结果的陈述；我们对合作伙伴关系、许可和/或合作安排以及我们已经达成或将来可能达成的其他战略安排和交易的潜在利益的期望；我们对里程碑、特许权使用费或现有协议下可能应付给第三方或来自第三方的其他付款的信念和期望；以及我们对未来收入、研发费用、资本要求和向第三方付款的估计。

These statements are based u.

这些声明基于美国。

Source: Arrowhead Pharmaceuticals, Inc.

来源：Arrowhead Pharmaceuticals，Inc。